Work

Guideline for Management of Vasculitis Syndrome (JCS 2008): Digest Version

Year: 2011
Type: article
Abstract: Background of the Guideline1 Classification of Vasculitis Syndromes Vasculitis syndromes are classified, according to the size of the affected vessels, into large-vessel, medium-vessel, and small-vessel vasculitis (Table 1).Large-sized vessel vasculitis, ie, vasculitis occurring in the aorta and its major branches to the extremities, the head and the neck, includes Takayasu arteritis and temporal arteritis.Medium-sized vessel vasculitis, ie, vasculitis occurring in the major arteries and their branches to the visceral organs, includes polyarteri-tis nodosa (PAN), Kawasaki disease, and Buerger disease.Small-sized vessel vasculitis occurs in the arterioles, capillaries, and venules.In some cases, small arteries are also affected.Small-sized vessel vasculitis is classified according to the involvement of immune complexes.Vasculitis involving immune complexes include Henoch-Schönlein purpura, essential cryoglobulinemia, and malignant rheumatoid arthritis (MRA) (rheumatoid vasculitis).Small-sized vessel vasculitis not involving immune complexes include microscopic polyangiitis (MPA), Wegener's granulomatosis, and allergic granulomatous angiitis.Since these three conditions are associated with the presence of marker antibodies, ie, *Described in the present guidelines.The six underlined diseases are investigated by the Specific Disease Study Group of the MHLW.Polyarteritis nodosa and microscopic polyangiitis were categorized collectively as "periarteritis nodosa" until 2005.From 2006 on, these diseases have been clearly distinguished.ANCA, antineutrophil cytoplasmic antibodies; MHLW, Ministry of Health, Labour and Welfare.Wegener's granulomatosis Buerger disease Takayasu arteritis Malignant rheumatoid arthritis Microscopic polyangiitis + Polyarteritis nodosa JCS Joint Working Group II.Systemic signs/symptoms: Body weight often de-creases due to persistent high fever.Patients complain of vague symptoms such as weakness and generalized malaise. 2) Localized Visceral Signs/SymptomsThe visceral signs/symptoms of vasculitis syndromes arise simultaneously (or sequentially) as signs/symptoms associated with multiple organs.Visceral signs/symptoms are caused by ischemia or hemorrhage due to injury of affected blood vessels, and differ in nature by size of the affected blood vessels (Table 2). i) Visceral Signs/Symptoms of Large-and Medium-Sized Vessel Vasculitis (Table 2-I):Since large-and medium-sized vessels run from the aorta to visceral organs, the signs/symptoms of vasculitis result from injury to organs supplied by the affected blood vessels, and include pulse deficit, jaw claudication, loss of vision, and acute abdomen.Injury of large-or medium-sized vessels in the kidneys causes rapidly progressive hypertension and renal insufficiency. ii) Visceral Signs/Symptoms of Small-Sized VesselVasculitis (Table 2-II): The characteristic skin finding of small-sized vessel vasculitis is palpable purpura that often develops in the lower limbs.Mononeuritis multiplex is a clinical manifestation of vasculitis of medium-or small-sized vessel arteries feeding the affected nerves.It may manifest as sensory disturbance such as hyperesthesia or hypoesthesia, and, when progressive, leads to motor disturbance that may cause a drop hand or foot.The clinical features of vasculitis in small-sized vessels of the kidneys include those of nephritis, such as hematuria, proteinuria, and cylindruria.When pulmonary alveolar hemorrhage due to arteriolitis or venulitis develops, patients may expectorate bloody, foamy sputum.JCS Joint Working Group (1) Pneumocystis Pneumonia 1) Criteria for Prophylaxis Against Pneumocystis Pneumonia in Patients With Autoimmune Disease Patients requiring primary prophylaxis • Patients aged ≥50 years • Patients receiving glucocorticoid Patients receiving prednisolone (PSL) at ≥1.2 mg/kg/day or receiving ≥0.8 mg/kg/day PSL in combination with immunosuppressive drugs.Criteria for discontinuation of prophylaxis: Patients whose dose of PSL is ≤0.4 mg/kg/day.• Patients receiving immunosuppressive drugs Patients receiving ≥0.8 mg/kg/day PSL or with a peripheral lymphocyte count of ≤500 / μL.Criteria for discontinuation of prophylaxis: Patients whose dose of PSL is ≤0.4 mg/kg/day or with a peripheral lymphocyte count of ≥500 / μL over time.
Language: English
Subfield: Rheumatology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4240583319
FWCI: 6.553
Cites: 135
Cited by: 178
Related to: 10